Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

05 giugno 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Jun 5, 2023 | 2023, Investors, Press Releases

More details

Philogen Announces Clinical Trial Collaboration with MSD

Jun 1, 2023 | 2023, Press Releases, Scientific

Nidlegy™_CTCSA_Merck_Press_Release_ENG

Philogen to attend the Antibody Engineering & Therapeutics Europe 2023 in Amsterdam on June 6-8, 2023

May 31, 2023 | 2023, Events, Scientific

Prof. Dr. Dario Neri (CEO and CSO), is giving a presentation on the 6th of June 2023 entitled “Immunocytokines with Activity on Demand”. Dr. Roberto De Luca (Head of Antibody Therapeutics) is giving a presentation on the 7th of June 2023 entitled “Engineering...

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand (Price Sensitive)

May 30, 2023 | 2023, Investors, Press Releases

More details

Sun Pharma e Philogen stipulano un Accordo di commercializzazione, Licenza e Fornitura in esclusiva per il prodotto innovativo Nidlegy™ in Europa, Australia e Nuova Zelanda (Price Sensitive)

May 30, 2023 | 2023, Investors, Press Releases

More details

29 maggio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

May 29, 2023 | 2023, Investors, Press Releases

More details
« Older Entries

Recent Posts

  • Philogen kindly invites you to attend a virtual briefing for analysts on 5 June 2023 to discuss the Company’s latest updates.
  • 05 giugno 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen Announces Clinical Trial Collaboration with MSD
  • Philogen to attend the Antibody Engineering & Therapeutics Europe 2023 in Amsterdam on June 6-8, 2023
  • Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand (Price Sensitive)

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it